Clinical Trials Logo

KIT Gene Mutation clinical trials

View clinical trials related to KIT Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT03171389 Recruiting - GIST, Malignant Clinical Trials

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

POETIG
Start date: March 22, 2017
Phase: Phase 2
Study type: Interventional

This is a non-randomized, open-label, multicenter phase 2 study to evaluate the efficacy and safety of ponatinib in patients with metastatic and/or unresectable GIST after prior failure or intolerability of imatinib. Patients will be enrolled into 1 of 2 cohorts based on absence (Cohort A) or presence (Cohort B) of KIT exon 13 resistance mutations as measured by liquid biopsy. A third cohort (Cohort C) will include patients who have received all approved lines of TKI treatments (imatinib, sunitinib and regorafenib).

NCT ID: NCT02260505 Completed - Clinical trials for Gastrointestinal Stromal Tumors

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

ImadGist
Start date: December 24, 2014
Phase: Phase 3
Study type: Interventional

This is a 2 arms study concerning patients with primary GIST who followed an Imatinib adjuvant treatment for 3 years after surgery and who have a high risk of recurrence. In the first arm, patients will continue Imatinib treatment for 3 more years, allowing to determine if the continuation of this treatment is efficient for disease control, in terms of Disease Free Survival improvement. In the second arm, patients will discontinue the Imatinib treatment, as standard practice. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease.